Association of circulating IGF-I and IGFBP-3 concentrations and exercise capacity in healthy volunteers: Results of the Study of Health in Pomerania

Growth Hormone and IGF Research

Volumn 20, Issue 6, 2010, Pages 404-410

  Gläser, Sven ^a   Friedrich, Nele ^b   Ewert, Ralf ^a   Schäper, Christoph ^a   Krebs, Alexander ^c   Dörr, Marcus ^a   Völzke, Henry ^a   Felix, Stephan B ^d   Nauck, Matthias ^c   Wallaschofski, Henri ^c   Koch, Beate ^a  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b Institute of Clinical Chemistry and Laboratory Medicine   (Germany)

^c Institute of Clinical Chemistry and Laboratory Medicine   (Germany)

^d Pulmonary Medicine and Infectious Diseases   (Germany)

Author keywords

Exercise capacity; IGF I; IGFBP 3; Mortality; Study of Health in Pomerania (SHIP)

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AEROBIC EXERCISE; AGED; ANAEROBIC THRESHOLD; ARTICLE; BODY MASS; BODY SIZE; CARDIOPULMONARY EXERCISE TEST; CONTROLLED STUDY; EXERCISE INTENSITY; EXERCISE PHYSIOLOGY; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MORTALITY; NORMAL HUMAN; OXYGEN CONSUMPTION; PHYSICAL ACTIVITY; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REPRODUCIBILITY; SEX DIFFERENCE; SMOKING HABIT;

ADULT; AGED; AGED, 80 AND OVER; ATHLETIC PERFORMANCE; EXERCISE; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; GERMANY; HEALTH; HUMAN EXPERIMENTATION; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; RESPIRATORY FUNCTION TESTS;

EID: 78649629839     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2010.09.002     Document Type: Article

References (43)

1. Adams G.R., Haddad F., Appl Physiol J. The relationships among IGF-1, DNA content, and protein accumulation during skeletal muscle hypertrophy. J. Appl. Physiol. 1996 Dec, 81(6):2509-2516.
2. Eliakim A., Brasel J.A., Barstow T.J., Mohan S., Cooper D.M. Peak oxygen uptake, muscle volume, and the growth hormone-insulin-like growth factor-I axis in adolescent males. Med. Sci. Sports Exerc. 1998 Apr, 30(4):512-517.
3. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 1995 Feb, 16(1):3-34.
4. Frystyk J. Exercise and the growth hormone-insulin-like growth factor axis. Med. Sci. Sports Exerc. 2010 Jan, 42(1):58-66.
5. Gibney J., Healy M.L., Sonksen P.H. The growth hormone/insulin-like growth factor-I axis in exercise and sport. Endocr. Rev. 2007 Oct, 28(6):603-624.
6. Eliakim A., Brasel J.A., Mohan S., Wong W.L., Cooper D.M., Physiol Am.J. Increased physical activity and the growth hormone-IGF-I axis in adolescent males. Am J Physiol 1998 Jul, 275(1 Pt 2):R308-R314.
7. Weltman A., Weltman J.Y., Hartman M.L., Abbott R.D., Rogol A.D., Evans W.S., et al. Relationship between age, percentage body fat, fitness, and 24-hour growth hormone release in healthy young adults: effects of gender. J. Clin. Endocrinol. Metab. 1994 Mar, 78(3):543-548.
8. Onder G., Liperoti R., Russo A., Soldato M., Capoluongo E., Volpato S., et al. Body mass index, free insulin-like growth factor I, and physical function among older adults: results from the ilSIRENTE study. Am. J. Physiol. Endocrinol. Metab. 2006 Oct, 291(4):E829-E834.
9. Velloso C.P. Regulation of muscle mass by growth hormone and IGF-I. Br. J. Pharmacol. 2008 Jun, 154(3):557-568.
10. Eliakim A., Brasel J.A., Mohan S., Barstow T.J., Berman N., Cooper D.M. Physical fitness, endurance training, and the growth hormone-insulin-like growth factor I system in adolescent females. J. Clin. Endocrinol. Metab. 1996 Nov, 81(11):3986-3992.
11. Nindl B.C., Headley S.A., Tuckow A.P., Pandorf C.E., Diamandi A., Khosravi M.J., et al. IGF-I system responses during 12weeks of resistance training in end-stage renal disease patients. Growth Horm. IGF Res. 2004 Jun, 14(3):245-250.
12. Nindl B.C., Pierce J.R. Insulin-like growth factor I as a biomarker of health, fitness, and training status. Med. Sci. Sports Exerc. 2010 Jan, 42(1):39-49.
13. Berggren A., Ehrnborg C., Rosen T., Ellegard L., Bengtsson B.A., Caidahl K. Short-term administration of supraphysiological recombinant human growth hormone (GH) does not increase maximum endurance exercise capacity in healthy, active young men and women with normal GH-insulin-like growth factor I axes. J. Clin. Endocrinol. Metab. 2005 Jun, 90(6):3268-3273.
14. Blackman M.R., Sorkin J.D., Munzer T., Bellantoni M.F., Busby-Whitehead J., Stevens T.E., et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 2002 Nov, 288(18):2282-2292.
15. Coleman M.E., DeMayo F., Yin K.C., Lee H.M., Geske R., Montgomery C., et al. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J. Biol. Chem. 1995 May 19, 270(20):12109-12116.
16. Hambrecht R., Schulze P.C., Gielen S., Linke A., Mobius-Winkler S., Erbs S., et al. Effects of exercise training on insulin-like growth factor-I expression in the skeletal muscle of non-cachectic patients with chronic heart failure. Eur. J. Cardiovasc. Prev. Rehabil. 2005 Aug, 12(4):401-406.
17. Wasserman K, Hansen JE, Sue DY, Stringer WW, Whipp BJ. Principles of Exercise Testing and Interpretation: Including Pathophysiology and Clinical Applications. 4th ed ed: Lippincott Williams and Wilkins; 2004.
18. Hsia C.C. Coordinated adaptation of oxygen transport in cardiopulmonary disease. Circulation 2001 Aug 21, 104(8):963-969.
19. Glaser S., Friedrich N., Ewert R., Schaper C., Nauck M., Dorr M., et al. Association between serum insulin-like growth factor (IGF) I and IGF binding protein-3 and lung function. J. Clin. Endocrinol. Metab. 2009 Jul, 94(7):2452-2458.
20. Keil U., Stieber J., Doring A., Chambless L., Hartel U., Filipiak B., et al. The cardiovascular risk factor profile in the study area Augsburg. Results from the first MONICA survey 1984/85. Acta Med. Scand. Suppl. 1988, 728:119-128.
21. Volzke H., Alte D., Schmidt C.O., Radke D., Lorbeer R., Friedrich N., et al. Cohort Profile: The Study of Health in Pomerania. Int. J. Epidemiol. 2010 Feb 18, [Electronic publication ahead of print].
22. von Elm E., Altman D.G., Egger M., Pocock S.J., Gotzsche P.C., Vandenbroucke J.P. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007 Oct 20, 370(9596):1453-1457.
23. Quanjer P.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Peslin R., Yernault J.C. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur. Respir. J. Suppl. 1993 Mar, 16:5-40.
24. Measuring obesity-classification and description of anthropometric data.Report on a WHO consultation of epidemiology of obesity 1987, Report No.
25. Jones N.L., Makrides L., Hitchcock C., Chypchar T., McCartney N. Normal standards for an incremental progressive cycle ergometer test. Am. Rev. Respir. Dis. 1985 May, 131(5):700-708.
26. Koch B., Schaper C., Ittermann T., Spielhagen T., Dorr M., Volzke H., et al. Reference values for cardiopulmonary exercise testing in healthy volunteers: the SHIP study. Eur. Respir. J. 2009 Feb, 33(2):389-397.
27. ATS/ACCP Statement on cardiopulmonary exercise testing. Am. J. Respir. Crit. Care Med. 2003 Jan 15, 167(2):211-277.
28. Palange P., Ward S.A., Carlsen K.H., Casaburi R., Gallagher C.G., Gosselink R., et al. Recommendations on the use of exercise testing in clinical practice. Eur. Respir. J. 2007 Jan, 29(1):185-209.
29. Meyer K., Westbrook S., Schwaibold M., Hajric R., Peters K., Roskamm H. Short-term reproducibility of cardiopulmonary measurements during exercise testing in patients with severe chronic heart failure. Am. Heart J. 1997 Jul, 134(1):20-26.
30. Hietaniemi M., Poykko S.M., Ukkola O., Paivansalo M., Antero Kesaniemi Y. IGF-I concentrations are positively associated with carotid artery atherosclerosis in women. Ann. Med. 2005, 37(5):373-382.
31. Span J.P., Pieters G.F., Sweep F.G., Hermus A.R., Smals A.G. Gender differences in rhGH-induced changes in body composition in GH-deficient adults. J. Clin. Endocrinol. Metab. 2001 Sep, 86(9):4161-4165.
32. Unden A.L., Elofsson S., Brismar K. Gender differences in the relation of insulin-like growth factor binding protein-1 to cardiovascular risk factors: a population-based study. Clin. Endocrinol. (Oxf) 2005 Jul, 63(1):94-102.
33. Kostek M.C., Delmonico M.J., Reichel J.B., Roth S.M., Douglass L., Ferrell R.E., et al. Muscle strength response to strength training is influenced by insulin-like growth factor 1 genotype in older adults. J. Appl. Physiol. 2005 Jun, 98(6):2147-2154.
34. Friedrich N, Aumann N, Dorr M, Felix SB, Nauck M, Wallaschofski H, et al. Lack of association between insulin-like growth factor-1 or insulin-like growth factor-binding protein-3 and left ventricular hypertrophy: results of the Study of Health in Pomerania. J Hypertens Apr;28(4):856-64.
35. Widdowson W.M., Gibney J. J. Clin. Endocrinol. Metab. 2008 Nov, 93(11):4413-4417.
36. Thomas S.G., Esposito J.G., Ezzat S. Exercise training benefits growth hormone (GH)-deficient adults in the absence or presence of GH treatment. J. Clin. Endocrinol. Metab. 2003 Dec, 88(12):5734-5738.
37. Brat O., Ziv I., Klinger B., Avraham M., Laron Z. Muscle force and endurance in untreated and human growth hormone or insulin-like growth factor-I-treated patients with growth hormone deficiency or Laron syndrome. Horm. Res. 1997, 47(2):45-48.
38. West R., Zatonski W., Przewozniak K., Jarvis M.J. Can we trust national smoking prevalence figures? Discrepancies between biochemically assessed and self-reported smoking rates in three countries. Cancer Epidemiol. Biomark. Prev. 2007 Apr, 16(4):820-822.
39. Frystyk J., Freda P., Clemmons D.R. The current status of IGF-I assays--a 2009 update. Growth Horm. IGF Res. 2010 Feb, 20(1):8-18.
40. Friedrich N., Alte D., Volzke H., Spilcke-Liss E., Ludemann J., Lerch M.M., et al. Reference ranges of serum IGF-1 and IGFBP-3 levels in a general adult population: results of the Study of Health in Pomerania (SHIP). Growth Horm. IGF Res. 2008 Jun, 18(3):228-237.
41. Friedrich N., Haring R., Nauck M., Ludemann J., Rosskopf D., Spilcke-Liss E., et al. Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations. J. Clin. Endocrinol. Metab. 2009 May, 94(5):1732-1739.
42. Juul A., Main K., Blum W.F., Lindholm J., Ranke M.B., Skakkebaek N.E. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol (Oxf) 1994 Jul, 41(1):85-93.
43. Frystyk J. Free insulin-like growth factors - measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm. IGF Res. 2004 Oct, 14(5):337-375.